MK0859

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Ambulatory Blood PressureHypercholesterolemiaHyperlipidemiaMixed Hyperlipemia

Phase 1

A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

CompletedNCT00565006

Merck Sharp & Dohme LLCAmbulatory Blood Pressure

Start: 2006-07-31End: 2006-09-30Updated: 2015-02-27

A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

CompletedNCT00565292

Merck Sharp & Dohme LLCHypercholesterolemia, Hyperlipidemia

Start: 2006-07-31End: 2006-08-31Updated: 2015-02-25

Phase 2

MK0859 Dose-Ranging Study (0859-003)

TerminatedNCT00325455

Merck Sharp & Dohme LLCHypercholesterolemia, Mixed Hyperlipemia

Start: 2006-06-30End: 2007-03-31Updated: 2015-03-02

Related Papers

Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.

2014-10-1314 citations

Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.

2007-12-01204 citations